Photys Therapeutics

What Photys Therapeutics does

Photys Therapeutics is a privately held, clinical-stage biopharmaceutical company developing a new class of bifunctional small-molecule medicines that modulate protein function through induced proximity. Founded in 2022 and headquartered in Waltham, Massachusetts, the company operates three proprietary platforms — PROTAC (PROteolysis-TArgeting Chimera) for target protein degradation, tPRIME (targeted-PRoximity-Induced Modulator of Expression) for transcriptional regulation, and PHICS (PHosphorylation-Inducing Chimeric Small molecules) for precise kinase-mediated phosphorylation — that collectively enable selective modulation of proteins historically considered "undruggable," with the additional capability of tissue- or cell compartment-selective delivery.

The company's scientific foundation was established through a $75 million Series A led by MPM Capital in September 2022, with participation from 8VC, Eli Lilly, Omega Funds, Longwood Fund, Mass General Brigham Ventures, MRL Ventures, Arkin Holdings, and Ono Venture. Its pipeline targets oncology, autoimmune and inflammatory diseases, cardiometabolic disease, and rare diseases, with a recently in-licensed Phase 1-ready IRAK4 degrader from Polymed (February 2025) representing its most advanced clinical asset, alongside a research collaboration with Novo Nordisk (December 2024) applying the PHICS platform to cardiometabolic indications.

Photys is pre-revenue and operates on a partnership and out-licensing model rather than direct commercialization. Revenue, when generated, is expected to flow from milestone payments, royalties, and potential co-development economics with pharmaceutical partners. The company was co-founded by Amit Choudhary of the Broad Institute and the Longwood Fund, and is led by Executive Chairperson Kazumi Shiosaki, with Alexandra Joseph, PhD appointed as Chief Scientific Officer in October 2024.

Name

Photys Therapeutics

Legal name

Photys Therapeutics

Website

https://photys.com

Company type

Private

Founded year

2022

Operating status

Operating

Headcount range

11–50 employees

Short description

Photys Therapeutics is a privately held, pre-revenue biopharmaceutical company developing bifunctional small molecules (PROTAC, tPRIME, PHICS platforms) that induce proximity to selectively modulate previously undruggable proteins, with pipeline assets in oncology, autoimmune, cardiometabolic, and rare diseases.

Ownership category

akta.pro rank

Product category

Biopharmaceuticals

NAICS

Pharmaceutical and Medicine Manufacturing (3254), Research and Development in Biotechnology (except Nanobiotechnology) (541714)

SIC

Pharmaceutical Preparations (2834)

akta.pro primary industry

Protein Engineering & Directed Evolution Platforms (enzyme/therapeutic protein optimization) (HLAAAIAC)

akta.pro secondary industry

Therapeutic Peptides & Protein/Peptide Biologics (HLAAAAAH)

Keywords

• Bifunctional small molecules
• Targeted protein degradation
• Proximity-based therapeutics
• Protein kinase modulators
• Drug discovery platforms

Headquarters

HQ city

Cambridge

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Technology or R&D, Operations, Supply Chain

Revenue model

1. Drug Development and Commercialization: Pre-revenue biotech company developing proprietary medicines through proprietary bifunctional platforms (PROTAC, tPRIME, PHICS) targeting oncology, autoimmune/inflammatory diseases, and cardiometabolic diseases. Revenue will be generated through eventual product sales, licensing deals, and co-development partnerships.
2. Partnerships and Collaborations: The company generates value through strategic partnerships with pharmaceutical companies including research collaborations (Novo Nordisk), exclusive license agreements (Polymed), and potential future co-development or out-licensing deals.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels4 records

Core offering

Photys Therapeutics develops proprietary bifunctional small-molecule medicines that induce proximity between a target disease-associated biomolecule and an effector biomolecule (such as an E3 ligase, transcriptional regulator, or kinase). Through three platforms — PROTAC for protein degradation, tPRIME for transcriptional regulation, and PHICS for precise phosphorylation — the company aims to selectively modulate 'undruggable' protein targets for oncology, autoimmune/inflammatory, and cardiometabolic diseases, with commercialization via pharmaceutical licensing and partnerships.

Product overview

Photys Therapeutics is a proximity-based therapeutics company with expertise across three bifunctional platforms: PROTAC (Target Protein Degrader), tPRIME (Target Protein Transcriptional Regulator), and PHICS (Target Protein Phosphorylator). These platforms create chimeric small molecules that induce proximity between a target biomolecule (e.g., disease-associated protein) and an effector biomolecule (such as a ligase, transcriptional regulator, or kinase). The company is advancing a pipeline of medicines for oncology, autoimmune and inflammatory diseases, and cardiometabolic diseases. The company also has a licensed Phase 1-ready IRAK4 degrader asset.

Differentiator

Problem solved

Functional benefit

Products and services

• PROTAC Platform (Target Protein Degrader) PROteolysis-TArgeting Chimera — a bifunctional small molecule that enhances pairing of specific ligases (such as an E3 ligase) with a specific target protein to degrade the target protein through ubiquitination, removing the protein from the cell to address disease associated with its presence or overactivity.
• tPRIME Platform (Target Protein Transcriptional Regulator) Targeted-PRoximity-Induced Modulator of Expression — a bifunctional small molecule that enhances the pairing of specific transcriptional regulatory proteins with a specific target to prime the DNA for transcription and enhance the activity of the target protein.
• PHICS Platform (Target Protein Phosphorylator) PHosphorylation-Inducing Chimeric Small molecules — a bifunctional small molecule that enhances the pairing of specific kinases with a specific target protein to induce precise and reproducible phosphorylation of a given amino acid, recapitulating or amplifying biology such as activation, degradation via phosphodegrons, stabilization, or translocation.
• IRAK4 Degrader (Pipeline Asset) A Phase 1-ready proximity-based IRAK4 protein degrader licensed exclusively from Polymed, advancing Photys' pipeline for treating inflammatory and autoimmune diseases.

Quantifiable outcome

• p53-Y220C-BET bifunctionals drive p53-Y220C-mutant cancer cells into apoptosis in vitro and in vivo
• +1 more outcomes

Segments4 records

Ideal customer profiles1 record

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Partnerships

Two partnerships are on record, tiered core.

• PolymedcoreOEM/ Whitelabel/ Licensing Partner · 20 February 2025Photys Therapeutics entered into an exclusive license agreement with Polymed for a Phase 1-ready IRAK4 degrader. This agreement further advances Photys' proximity-based pipeline, enabling the company to leverage its bifunctional molecule expertise for inflammatory and autoimmune disease applications.
• Novo NordiskcoreStrategic or Co-development Partner · 18 December 2024Photys Therapeutics announced a research collaboration with Novo Nordisk to develop induced proximity PHICS technology for cardiometabolic diseases. This collaboration leverages Photys' PHICS platform to create novel therapeutics for metabolic disorders using precision phosphorylation modulation.

Scale indicators3 records

Recent moves3 records

Expansion highlights5 records

Direct peers

• Arvinas: Arvinas is the pioneer of PROTAC-based targeted protein degradation, with clinical-stage assets in oncology (vepdegestrant with Pfizer). It is the most directly comparable peer to Photys' PROTAC platform and overall proximity-induced therapeutics strategy.
• Kymera Therapeutics: Kymera is a clinical-stage biotech developing heterobifunctional degraders (Pegasus platform) across oncology and immunology, including an IRAK4 degrader (KT-474) — directly overlapping with Photys' IRAK4 program and broader immunology focus.
• Nurix Therapeutics: Nurix is a clinical-stage targeted protein degradation company (DELigase platform) with oncology and immunology pipeline assets, including collaborations with Sanofi and Gilead. Comparable as a direct peer in the PROTAC / induced-proximity space.
• C4 Therapeutics: C4 Therapeutics is a clinical-stage targeted protein degradation company with a TORPEDO platform for bifunctional degraders, pursuing oncology indications. Directly comparable technology and business model to Photys.
• Monte Rosa Therapeutics: Monte Rosa is a clinical-stage biotech developing molecular glue degraders (QuEEN discovery engine) for oncology and inflammatory diseases. Closely comparable as an induced-proximity therapeutics peer, though focused on molecular glues rather than bifunctional molecules.
• Foghorn Therapeutics: Foghorn is a clinical-stage chromatin biology company using its Gene Traffic Control platform to develop oncology therapies, with multiple partnered programs (e.g., with Merck, Lilly). Comparable as a Boston-area proximity/chromatin-focused peer.
• Amphista Therapeutics: Amphista is a UK-based targeted protein degradation company developing next-generation bifunctional molecules with a focus on differentiated E3 ligase usage. Comparable as an emerging peer in the proximity-induced therapeutics space.

Emerging players

• Captor Therapeutics: Captor Therapeutics is a clinical-stage Polish biotech developing targeted protein degraders (OptiTDC platform) for oncology and neurodegenerative diseases. Comparable as a peer in the bifunctional degradation space, with a slightly different geographic and stage profile.
• Vicinitas Therapeutics: Vicinitas Therapeutics is an early-stage biotech developing targeted protein stabilizers and degraders (DUBAC platform). Comparable as an emerging peer in induced-proximity therapeutics with adjacent mechanism.
• Rapafusyn Pharmaceuticals: Rapafusyn is a Johns Hopkins spin-out developing macrocyclic and proximity-induced therapeutics, with a focus on non-PROTAC induced proximity mechanisms. Comparable as an emerging peer in the broader induced-proximity space.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat3 records

Key risks5 records

Key highlights6 records

Customer concentration

• LinkedInlinkedin.com/company/photys

Revenue estimate

Valuation estimate

Number of profiles

Profiles11 records

Funding overview

Funding rounds1 record

Investors10 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Photys Therapeutics